LOGO
LOGO

Corporate News

Bluebird Bio Stock Plunges 40% On Acquisition Deal By Carlyle And SK Capital

By RTTNews Staff Writer   ✉   | Published:   | Follow Us On Google News
rttnewslogo20mar2024

bluebird bio, Inc. (BLUE) is down 40.17 percent during Friday's trading, falling $2.83 to trade at $4.21 after announcing a definitive agreement to be acquired by Carlyle and SK Capital Partners.

The stock opened at $4.91 and has traded between $4.00 and $5.65 today. Volume has surged to 4.27 million shares, well above its average of 392,053. BLUE's 52-week range is $4.00 to $38.40.

The deal includes a leadership transition, with David Meek expected to become CEO upon closing.

For comments and feedback contact: editorial@rttnews.com

Business News

Invest in the Best Pharma Stocks by Subscribing to RTT Biotech Investor.
Global Economics Weekly Update: April 13 – April 17, 2026

April 17, 2026 15:29 ET
The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.